RxDoctor Payments Data

Luning Chen, MD

Family Medicine · Alhambra, CANPI 1306956529

Payments from drug & device makers

$5,527in general payments, 2019–2025

Across 213 payments — averaging $25.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$1K
  • AbbVie$522
  • Nestle Healthcare Nutrition Inc.$380
  • Lilly USA, LLC$294
  • Amarin Pharma, Inc.$215
  • plus $963 from 14 others

What the payments were for

  • Food & beverage$5,49799%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,527 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$134,481
Medicare patients
140
Services billed
1,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol152$89,937
JanuviaSitagliptin Phosphate63$47,315
CreonLipase/Protease/Amylase37$37,972
RestasisCyclosporine40$26,262
LinzessLinaclotide42$23,217
Janumet XrSitagliptin Phos/Metformin Hcl39$21,200
JardianceEmpagliflozin22$18,303
VascepaIcosapent Ethyl69$17,773
JanumetSitagliptin Phos/Metformin Hcl22$13,561
DapagliflozinDapagliflozin Propanediol28$12,546
Cyclosporine21$12,409
Diclofenac Sodium25$10,977
Xigduo XrDapaglifloz Propaned/Metformin24$10,030
Icosapent Ethyl57$8,528
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$7,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,835$89,937152 claims
AbbVieCreon, Restasis, Linzess$522$87,451119 claims
MerckJanuvia, Janumet Xr, Janumet$21$82,077124 claims
Boehringer IngelheimJardiance$39$18,30322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Alhambra

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →